Drug Profile

Bispecific antibody therapeutic - XOMA

Latest Information Update: 17 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lava Therapeutics
Developer Amsterdam UMC; Monash University; XOMA
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Natural killer cell stimulants; Natural killer T cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Jul 2026 XOMA has been acquired by Ligand Pharmaceuticals
28 Oct 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Australia (Parenteral)
28 Oct 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Netherlands (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com